◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Guangzhou Innogen Pharmaceutical Group Co., Ltd (2591) Financial History

Name: Guangzhou Innogen Pharmaceutical Group Co., Ltd (2591) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

Guangzhou Innogen Pharmaceutical Group Co., Ltd (2591) operates in the Biotechnology industry and is headquartered in Shanghai, China with about 193 employees. Its market capitalization is roughly CNY 3 billion. In the fiscal year ended 2025-12-31, 2591 reported CNY 132M in revenue and (CNY 341M) in net income.

Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products.

Interactive charts & full statements →

2591 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31
Total Revenue	CNY 132M	CNY 0M	CNY 0M
Gross Profit	CNY 117M	CNY 0M	CNY 0M
Operating Income (EBIT)	(CNY 343M)	(CNY 189M)	(CNY 747M)
Net Income	(CNY 341M)	(CNY 175M)	(CNY 733M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2591 Free Cash Flow History

2591 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31
Total Assets	CNY 1.6B	CNY 935M	CNY 1.1B
Total Liabilities	CNY 518M	CNY 138M	CNY 400M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2591 viewer.

Other Companies in Biotechnology

2342 · Transgenic Group Inc. — $4 billion
RCUS · Arcus Biosciences, Inc. — $4 billion
IDYA · IDEAYA Biosciences, Inc. — $4 billion
ALMS · Alumis Inc. — $4 billion
CLDX · Celldex Therapeutics, Inc. — $3 billion
NAMS · NewAmsterdam Pharma Company N.V. — $3 billion
MBX · MBX Biosciences, Inc. — $3 billion
2105 · Laekna, Inc. — $3 billion

← 2590 All “0-9” companies 2592 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.